The SEMA3D antibody is designed to target Semaphorin-3D (SEMA3D), a secreted glycoprotein belonging to the semaphorin family, which plays critical roles in axon guidance, cell migration, and tissue development. SEMA3D is a class 3 semaphorin characterized by a conserved Sema domain and a C-terminal immunoglobulin-like fold. It functions as a signaling molecule by binding to receptors such as plexins and neuropilins, modulating cellular processes like cytoskeletal reorganization and adhesion. Dysregulation of SEMA3D has been implicated in various pathologies, including cancer metastasis, cardiovascular diseases, and neurological disorders, due to its influence on angiogenesis, tumor microenvironment interactions, and neural circuit formation.
Antibodies against SEMA3D are essential tools for studying its expression, localization, and functional mechanisms. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to visualize protein distribution in tissues or cultured cells. Research utilizing SEMA3D antibodies has revealed its dual role as both a chemorepellent and chemoattractant, depending on cellular context and receptor complexes. Recent studies highlight its potential as a biomarker for certain cancers, where elevated SEMA3D levels correlate with aggressive phenotypes. Additionally, these antibodies aid in exploring therapeutic strategies targeting SEMA3D-mediated pathways to inhibit tumor progression or promote nerve regeneration. The development and validation of SEMA3D-specific antibodies continue to advance our understanding of its physiological and pathological significance.